| Mingi Choi, MD | |
|
1 Robertson Drive, Suite 24, Bedminster, NJ 07921 | |
| (908) 378-3223 | |
| (908) 722-6318 |
| Full Name | Mingi Choi |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 37 Years |
| Location | 1 Robertson Drive, Bedminster, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902802846 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 25MA05758800 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Igea Brain And Spine Pa | 2769418037 | 11 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston.
Researchers at the Duke Human Vaccine Institute have led an effort to develop a more accurate way to gauge the incidence of HIV infections in large populations, which will improve research and prevention strategies worldwide.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
› Verified 7 days ago
| Entity Name | Physical Medicine And Rehabilitation Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831110469 PECOS PAC ID: 1658273750 Enrollment ID: O20040121000094 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston.
Researchers at the Duke Human Vaccine Institute have led an effort to develop a more accurate way to gauge the incidence of HIV infections in large populations, which will improve research and prevention strategies worldwide.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
› Verified 7 days ago
| Entity Name | Somerset Orthopedic Associates, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104909662 PECOS PAC ID: 7517947575 Enrollment ID: O20040721001194 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston.
Researchers at the Duke Human Vaccine Institute have led an effort to develop a more accurate way to gauge the incidence of HIV infections in large populations, which will improve research and prevention strategies worldwide.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
› Verified 7 days ago
| Entity Name | Igea Brain & Spine Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710103288 PECOS PAC ID: 2769418037 Enrollment ID: O20050711000028 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston.
Researchers at the Duke Human Vaccine Institute have led an effort to develop a more accurate way to gauge the incidence of HIV infections in large populations, which will improve research and prevention strategies worldwide.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
› Verified 7 days ago
| Entity Name | Somerset Orthopedics & Sports Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881057123 PECOS PAC ID: 2062709603 Enrollment ID: O20160924000019 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston.
Researchers at the Duke Human Vaccine Institute have led an effort to develop a more accurate way to gauge the incidence of HIV infections in large populations, which will improve research and prevention strategies worldwide.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mingi Choi, MD 1 Robertson Drive, Suite 24, Bedminster, NJ 07921 Ph: (908) 378-3223 | Mingi Choi, MD 1 Robertson Drive, Suite 24, Bedminster, NJ 07921 Ph: (908) 378-3223 |
News Archive
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.
Cancer is an unwelcome blow for anyone, but those diagnosed with cancer who live in low-income and rural areas face an increased risk of suicide compared with those living in high-income and urban areas, according to a study by The University of Texas Health Science Center at Houston.
Researchers at the Duke Human Vaccine Institute have led an effort to develop a more accurate way to gauge the incidence of HIV infections in large populations, which will improve research and prevention strategies worldwide.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
› Verified 7 days ago